問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Taipei Veterans General Hospital

List

2213Cases

2008-10-01 - 2010-12-31

Phase IV

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2008-09-01 - 2009-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Terminated14Sites

2018-04-03 - 2019-04-30

Phase I

A Phease1, Multicenter, Open-Label, Single Sequence Crossover Study to Evaluate Drug-Drug Interaction Potential of OATP1B/CYP3A Inhibitor on The Pharmacokinetics of DS-8201a in Subjects with HER2-Expressing Advanced Solid Malignant Tumors 一項第一期、多中心、開放標示、單一順序交叉試驗，評估在HER2表現型晚期實質惡性腫瘤受試者中，OATP1B/CYP3A抑制劑對DS-8201a藥物動力學發生藥物交互作用的可能性

  • Condition/Disease

    Advanced Solid Malignant Tumors

  • Test Drug

    DS-8201a

Participate Sites
3Sites

Terminated3Sites

2018-04-01 - 2019-09-30

Phase I

Phase 1, Multicenter, Open-label Study of DS-8201a to Assess Safety and Pharmacokinetics in Subjects With HER2-Positive Advanced and/or Refractory Gastric, Gastroesophageal Junction Adenocarcinoma, or Breast Cancer

  • Condition/Disease

    Gastric, Gastroesophageal Junction Adenocarcinoma, or Breast Cancer

  • Test Drug

    DS-8201a

Participate Sites
2Sites

Terminated2Sites

趙毅
Taipei Veterans General Hospital

2015-03-01 - 2017-05-31

Phase III

An Asian, Phase III, multicenter, randomized, double-blind, placebo-controlled, 14-week trial to evaluate the efficacy of DS-5565 in patients with diabetic peripheral neuropathy pain (DPNP), followed by a 52-week open period Mark the extension test.

  • Condition/Disease

    Diabetic peripheral neuropathy pain

  • Test Drug

    DS-5565

Participate Sites
17Sites

Terminated17Sites

2015-03-01 - 2017-05-31

Phase III

AN ASIAN, PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED 14-WEEK STUDY OF DS-5565 IN PATIENTS WITH POST-HERPETIC NEURALGIA FOLLOWED BY A 52-WEEK OPEN-LABEL EXTENSION

  • Condition/Disease

    POST-HERPETIC NEURALGIA

  • Test Drug

    DS-5565

Participate Sites
14Sites

Terminated14Sites

2016-08-31 - 2018-12-31

Phase III

A Randomized, Open-label, Japan-Korea-Taiwan Collaborative Phase 3 Study to Compare the Efficacy of Nimotuzumab and Irinotecan Combination Therapy versus Irinotecan Monotherapy as Second Line Treatment in Subjects with Advanced or Recurrent Gastric and Gastroesophageal Junction Cancer

  • Condition/Disease

    Advanced or Recurrent Gastric and Gastroesophageal Junction Cancer

  • Test Drug

    DE-766 injection 50 mg/10mL vial

Participate Sites
11Sites

Terminated10Sites

趙毅
Taipei Veterans General Hospital

2020-08-01 - 2022-08-31

Phase I/II

A Phase I/II, Open Label, Dose Escalation and Cohort Expansion Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of OBI 888 in Patients with Locally Advanced or Metastatic Solid Tumors.

  • Condition/Disease

    Metastatic Solid Tumors / Locally Advanced Solid Tumors

  • Test Drug

    OBI 888

Participate Sites
3Sites

Not yet recruiting2Sites

Recruiting1Sites

2018-05-30 - 2022-12-31

Phase II

An Open-label Phase 2 Trial of Dual TORC1/TORC2 Inhibitor ATG-008 in HBV+ Advanced Hepatocellular Carcinoma (HCC) Subjects Who Have Received at Least One Prior Line of Systemic Therapy (TORCH)

  • Condition/Disease

    Hepatocellular Carcinoma (HCC)

  • Test Drug

    ATG-008

Participate Sites
6Sites

Recruiting5Sites

楊再勝
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2016-10-16 - 2018-12-31

Phase I/II

A Phase 1/2, Open-label, Multicenter Study to Evaluate Safety, Tolerability,Pharmacokinetics and Efficacy of Oral Once-Daily Administration of HS-10296 in Patients with Locally Advanced or Metastatic Non-Small-Cell Lung Cancer Who Have Progressed Following Prior Therapy with an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Agent

  • Condition/Disease

    Non-small cell lung cancer

  • Test Drug

    HS-10296

Participate Sites
9Sites

Terminated8Sites

楊政達
Linkou Chang Gung Medical Foundation

Division of Thoracic Medicine

邱昭華
Taipei Veterans General Hospital

Division of Thoracic Medicine

1 201 202 203 204 205 222
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB